|
gptkbp:instanceOf
|
gptkb:Malignant_neoplasm
gptkb:brain_tumor
|
|
gptkbp:alternativeName
|
gptkb:Malignant_glioma
gptkb:HGG
|
|
gptkbp:associatedWith
|
Necrosis
Edema
Contrast enhancement on MRI
Microvascular proliferation
|
|
gptkbp:characterizedBy
|
Rapid growth
Infiltrative nature
|
|
gptkbp:class
|
gptkb:WHO_classification
|
|
gptkbp:grades
|
gptkb:WHO_grade_III
gptkb:WHO_grade_IV
|
|
gptkbp:hasDiagnosticMethod
|
MRI
Biopsy
|
|
gptkbp:hasEpidemiology
|
More common in adults
Slight male predominance
|
|
gptkbp:hasLocation
|
gptkb:Brain
gptkb:Central_nervous_system
|
|
gptkbp:hasMedianSurvival
|
12-18 months (glioblastoma)
2-3 years (anaplastic astrocytoma)
|
|
gptkbp:hasPrognosticMarker
|
MGMT promoter methylation
IDH mutation status
|
|
gptkbp:hasSurvivalRate
|
Low
|
|
gptkbp:mutationAssociatedWith
|
gptkb:TP53_mutation
gptkb:1p/19q_codeletion
gptkb:IDH_mutation
EGFR amplification
|
|
gptkbp:prognosis
|
Poor
|
|
gptkbp:recurrence
|
High
|
|
gptkbp:riskFactor
|
gptkb:Ionizing_radiation
Genetic predisposition
|
|
gptkbp:studiedIn
|
Neuro-oncology
|
|
gptkbp:subspecies
|
gptkb:Anaplastic_astrocytoma
gptkb:Anaplastic_oligodendroglioma
gptkb:Glioblastoma
|
|
gptkbp:symptom
|
Headache
Seizures
Cognitive impairment
Focal neurological deficits
|
|
gptkbp:treatment
|
gptkb:Temozolomide
gptkb:Carmustine_wafers
gptkb:Bevacizumab
Chemotherapy
Radiotherapy
Surgical resection
|
|
gptkbp:bfsParent
|
gptkb:HGG
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
High-grade glioma
|